董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Edward Mathers | 男 | Independent Director | 65 | 4.50万美元 | 未持股 | 2025-10-31 |
| James Flynn | 男 | Independent Director | 45 | 3.67万美元 | 未持股 | 2025-10-31 |
| Richard P. Shea | 男 | Independent Director | 73 | 5.50万美元 | 未持股 | 2025-10-31 |
| Peter Barrett | 男 | Chairman of the Board and Independent Director | 72 | 8.15万美元 | 未持股 | 2025-10-31 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Mary Beth Dooley | 女 | Principal Executive Officer and Principal Financial Officer | 44 | 48.65万美元 | 未持股 | 2025-10-31 |
董事简历
中英对照 | 中文 | 英文- Edward Mathers
-
Edward Mathers，自Senti Biosciences，Inc.业务合并于2022年6月结束以来一直担任Senti Biosciences，Inc.董事会成员，在Senti Biosciences，Inc.业务合并之前，自2016年7月起担任Legacy Senti董事会成员。Mathers先生自2019年11月起担任New Enterprise Associates，Inc.（NEA）的普通合伙人，该公司是一家专注于技术和医疗保健投资的私营风险投资公司，在此之前，于2008年8月至2019年10月担任NEA的合伙人。在加入NEA之前，Mathers先生曾在生物制药公司MedImmune，Inc.担任企业发展和风险投资执行副总裁，并于2008年6月至2022年6月期间领导其风险投资子公司MedImmune Ventures，Inc.。Mathers先生目前担任Affinia Therapeutics，Code Biotherapeutics，Inc.，Inozyme Pharma, Inc.（NASDAQ：INZY），Inversago Pharma，MBX Biosciences，Inc.，ObsEva SA（NASDAQ：OBSV），Reneo Pharmaceuticals, Inc.（NASDAQ：RPHM），TERM4（NASDAQ：TERM5），Rhythm Pharmaceuticals, Inc.TERM6（NASDAQ：RYTM），Shape Therapeutics Inc.，Sorriso Pharmaceuticals，Inc.，SpliceBio，SL，Synlogic, Inc.TERM8（NASDAQ：SYBX）原名自2017年10月至2022年12月被上市生物制药公司礼来 and Company（NYSE：LLY）、Mirum Pharmaceuticals, Inc.，Inc.（NASDAQ：MIRM）收购，自2018年11月至2022年9月，上市生物制药公司Lumos Pharma, Inc.，TERM4，Inc.（NASDAQ：LUMO）于2014年1月至2020年3月与NewLink Genetics Corporation（NASDAQ：NLINK）、Liquidia Technologies, Inc.TERM6（NASDAQ：LQDA）合并，上市生物制药公司TERM6，Inc.（NASDAQ：TERM7）于2009年4月至2019年5月被上市生物制药公司收购，而Ra Pharmaceuticals, Inc.，Inc.（NASDAQ：RARX）于2010年2月至2020年4月被UCIC收购马瑟斯先生在北卡罗来纳州立大学获得化学学士学位。
Edward Mathers has served as a member of Synlogic, Inc. Board since October 2012. Mr. Mathers previoly served on the Private Synlogic board of directors since July 2014. Mr. Mathers is a General Partner at NEA, a private venture capital firm focing on technology and healthcare investments. Mr. Mathers serves on the board of directors of the following publicly traded pharmaceutical companies: Trevi Therapeutics, Inc., Rhythm Pharmaceuticals, Inc., OnKure Therapeutics, Inc., formerly known as Reneo Pharmaceuticals, Inc., MBX Biosciences, Inc. and Senti Biosciences, Inc. Mr. Mathers also serves on the board of directors of several privately held companies. Mr. Mathers previoly served on the board of directors of the following publicly traded companies: ObsEva SA, Mirum Pharmaceuticals, Inc., Akouos, Inc., Lumos Pharma, Inc., and Ra Pharmaceuticals, Inc. From 2002 to 2008, Mr. Mathers served as Executive Vice President, Corporate Development and Venture at MedImmune, Inc., a biopharmaceutical company, and led its venture capital subsidiary, MedImmune Ventures, Inc. Before joining MedImmune in 2002, Mr. Mathers was Vice President, Marketing and Corporate Licensing and Acquisitions at Inhale Therapeutic Systems, a biotechnology company. Previoly, Mr. Mathers spent 15 years at Glaxo llcome, Inc. (GlaxoSmithKline), a pharmaceutical company, where he held vario sales and marketing positions. Mr. Mathers received a B.S. in Chemistry from North Carolina State University. - Edward Mathers，自Senti Biosciences，Inc.业务合并于2022年6月结束以来一直担任Senti Biosciences，Inc.董事会成员，在Senti Biosciences，Inc.业务合并之前，自2016年7月起担任Legacy Senti董事会成员。Mathers先生自2019年11月起担任New Enterprise Associates，Inc.（NEA）的普通合伙人，该公司是一家专注于技术和医疗保健投资的私营风险投资公司，在此之前，于2008年8月至2019年10月担任NEA的合伙人。在加入NEA之前，Mathers先生曾在生物制药公司MedImmune，Inc.担任企业发展和风险投资执行副总裁，并于2008年6月至2022年6月期间领导其风险投资子公司MedImmune Ventures，Inc.。Mathers先生目前担任Affinia Therapeutics，Code Biotherapeutics，Inc.，Inozyme Pharma, Inc.（NASDAQ：INZY），Inversago Pharma，MBX Biosciences，Inc.，ObsEva SA（NASDAQ：OBSV），Reneo Pharmaceuticals, Inc.（NASDAQ：RPHM），TERM4（NASDAQ：TERM5），Rhythm Pharmaceuticals, Inc.TERM6（NASDAQ：RYTM），Shape Therapeutics Inc.，Sorriso Pharmaceuticals，Inc.，SpliceBio，SL，Synlogic, Inc.TERM8（NASDAQ：SYBX）原名自2017年10月至2022年12月被上市生物制药公司礼来 and Company（NYSE：LLY）、Mirum Pharmaceuticals, Inc.，Inc.（NASDAQ：MIRM）收购，自2018年11月至2022年9月，上市生物制药公司Lumos Pharma, Inc.，TERM4，Inc.（NASDAQ：LUMO）于2014年1月至2020年3月与NewLink Genetics Corporation（NASDAQ：NLINK）、Liquidia Technologies, Inc.TERM6（NASDAQ：LQDA）合并，上市生物制药公司TERM6，Inc.（NASDAQ：TERM7）于2009年4月至2019年5月被上市生物制药公司收购，而Ra Pharmaceuticals, Inc.，Inc.（NASDAQ：RARX）于2010年2月至2020年4月被UCIC收购马瑟斯先生在北卡罗来纳州立大学获得化学学士学位。
- Edward Mathers has served as a member of Synlogic, Inc. Board since October 2012. Mr. Mathers previoly served on the Private Synlogic board of directors since July 2014. Mr. Mathers is a General Partner at NEA, a private venture capital firm focing on technology and healthcare investments. Mr. Mathers serves on the board of directors of the following publicly traded pharmaceutical companies: Trevi Therapeutics, Inc., Rhythm Pharmaceuticals, Inc., OnKure Therapeutics, Inc., formerly known as Reneo Pharmaceuticals, Inc., MBX Biosciences, Inc. and Senti Biosciences, Inc. Mr. Mathers also serves on the board of directors of several privately held companies. Mr. Mathers previoly served on the board of directors of the following publicly traded companies: ObsEva SA, Mirum Pharmaceuticals, Inc., Akouos, Inc., Lumos Pharma, Inc., and Ra Pharmaceuticals, Inc. From 2002 to 2008, Mr. Mathers served as Executive Vice President, Corporate Development and Venture at MedImmune, Inc., a biopharmaceutical company, and led its venture capital subsidiary, MedImmune Ventures, Inc. Before joining MedImmune in 2002, Mr. Mathers was Vice President, Marketing and Corporate Licensing and Acquisitions at Inhale Therapeutic Systems, a biotechnology company. Previoly, Mr. Mathers spent 15 years at Glaxo llcome, Inc. (GlaxoSmithKline), a pharmaceutical company, where he held vario sales and marketing positions. Mr. Mathers received a B.S. in Chemistry from North Carolina State University.
- James Flynn
-
詹姆斯·弗林如果当选，将成为董事会成员，自2022年年会起生效。Flynn先生目前是Nerium Capital LLC的管理成员和投资组合经理，Nerium Capital LLC是他于2021年创立的投资顾问。Nerium Capital LLC是Nerium Partners LP的普通合伙人，这是一家专注于医疗保健的投资合伙企业。Flynn先生目前还担任Axiom Health的董事会成员，该公司自2022年起为医疗保健行业提供软件和大数据解决方案，并自2020年起担任该公司的顾问。2017年至2018年，弗林先生在一家投资公司Aptigon Capital a Citadel Company担任治疗分析师。在此之前，Flynn先生于2003年至2017年在投资公司Amici Capital，LLC担任过多个职务，包括医疗保健投资组合经理（2008年至2017年）。从2002年到2003年，Flynn先生在投资公司Putnam Investments的信贷研究/高收益小组工作。Flynn先生在麻省理工学院（MIT）获得管理科学学士学位，主修金融学，辅修经济科学。Flynn先生是特许金融分析师（CFA）的持证人。
James Flynn has served as a member of Synlogic, Inc. Board since March 2024. Mr. Flynn is currently a Managing Member and Portfolio Manager of Nerium Capital LLC, an investment adviser he founded in 2021. Mr. Flynn also currently serves on the board of directors of Lite Strategy, Inc (NASDAQ: LITS), a pharmaceutical and digital asset treasury company, since 2023, and RiceBran Technologies, an innovative specialty ingredients company, since 2024. Previoly, Mr. Flynn served on the board of directors of ARCA Biopharma and Axiom Health, Inc. Prior to that, Mr. Flynn worked in vario investment management roles at Aptigon Capital (a division of Citadel LLC), Amici Capital, LLC, and Putnam Investments LLC. Mr. Flynn earned a S.B. degree in Management Science with a concentration in Finance and a minor in Economic Science from the Massachetts Institute of Technology. Mr. Flynn is a Chartered Financial Analyst (CFA) charterholder. - 詹姆斯·弗林如果当选，将成为董事会成员，自2022年年会起生效。Flynn先生目前是Nerium Capital LLC的管理成员和投资组合经理，Nerium Capital LLC是他于2021年创立的投资顾问。Nerium Capital LLC是Nerium Partners LP的普通合伙人，这是一家专注于医疗保健的投资合伙企业。Flynn先生目前还担任Axiom Health的董事会成员，该公司自2022年起为医疗保健行业提供软件和大数据解决方案，并自2020年起担任该公司的顾问。2017年至2018年，弗林先生在一家投资公司Aptigon Capital a Citadel Company担任治疗分析师。在此之前，Flynn先生于2003年至2017年在投资公司Amici Capital，LLC担任过多个职务，包括医疗保健投资组合经理（2008年至2017年）。从2002年到2003年，Flynn先生在投资公司Putnam Investments的信贷研究/高收益小组工作。Flynn先生在麻省理工学院（MIT）获得管理科学学士学位，主修金融学，辅修经济科学。Flynn先生是特许金融分析师（CFA）的持证人。
- James Flynn has served as a member of Synlogic, Inc. Board since March 2024. Mr. Flynn is currently a Managing Member and Portfolio Manager of Nerium Capital LLC, an investment adviser he founded in 2021. Mr. Flynn also currently serves on the board of directors of Lite Strategy, Inc (NASDAQ: LITS), a pharmaceutical and digital asset treasury company, since 2023, and RiceBran Technologies, an innovative specialty ingredients company, since 2024. Previoly, Mr. Flynn served on the board of directors of ARCA Biopharma and Axiom Health, Inc. Prior to that, Mr. Flynn worked in vario investment management roles at Aptigon Capital (a division of Citadel LLC), Amici Capital, LLC, and Putnam Investments LLC. Mr. Flynn earned a S.B. degree in Management Science with a concentration in Finance and a minor in Economic Science from the Massachetts Institute of Technology. Mr. Flynn is a Chartered Financial Analyst (CFA) charterholder.
- Richard P. Shea
-
Richard P. Shea自2017年8月28日合并结束以来，一直担任Synlogic, Inc.董事会成员。Shea先生于2017年2月至2020年7月担任Syndax制药，Inc.的首席财务官。Shea Previoly先生于2014年1月至2017年2月担任Syndax制药董事会成员。从2007年7月到2016年12月，Shea先生在一家上市的生物技术公司Momenta Pharmaceuticals Inc.担任高级副总裁兼首席财务官，自2003年10月起担任其副总裁兼首席财务官。在加入Momenta之前，Shea先生曾在上市的药物基因组学公司Variagenics Inc.担任首席运营官和首席财务官，在上市的生物技术公司Genetics Institute，Inc.担任财务副总裁。Shea先生获得了Princeton大学的文学学士学位和波士顿大学公共管理项目的工商管理硕士学位。
Richard P. Shea has served as a member of Synlogic, Inc. Board since the Merger closed on Augt 28, 2017. Mr. Shea served as the Chief Financial Officer of Syndax Pharmaceuticals, Inc. from February 2017 through July 2020. Mr. Shea previoly served as a member of the Syndax Pharmaceuticals board of directors from January 2014 to February 2017. From July 2007 through December 2016, Mr. Shea served as Senior Vice President and Chief Financial Officer of Momenta Pharmaceuticals Inc., a publicly traded biotechnology company, and was its Vice President and Chief Financial Officer since October 2003. Prior to joining Momenta, Mr. Shea served as Chief Operating Officer and Chief Financial Officer of Variagenics Inc., a publicly traded pharmacogenomics company, and as Vice President, Finance of Genetics Institute, Inc., a publicly traded biotechnology company. Mr. Shea received an A.B. from Princeton University and an M.B.A. from the Public Management Program at Boston University. - Richard P. Shea自2017年8月28日合并结束以来，一直担任Synlogic, Inc.董事会成员。Shea先生于2017年2月至2020年7月担任Syndax制药，Inc.的首席财务官。Shea Previoly先生于2014年1月至2017年2月担任Syndax制药董事会成员。从2007年7月到2016年12月，Shea先生在一家上市的生物技术公司Momenta Pharmaceuticals Inc.担任高级副总裁兼首席财务官，自2003年10月起担任其副总裁兼首席财务官。在加入Momenta之前，Shea先生曾在上市的药物基因组学公司Variagenics Inc.担任首席运营官和首席财务官，在上市的生物技术公司Genetics Institute，Inc.担任财务副总裁。Shea先生获得了Princeton大学的文学学士学位和波士顿大学公共管理项目的工商管理硕士学位。
- Richard P. Shea has served as a member of Synlogic, Inc. Board since the Merger closed on Augt 28, 2017. Mr. Shea served as the Chief Financial Officer of Syndax Pharmaceuticals, Inc. from February 2017 through July 2020. Mr. Shea previoly served as a member of the Syndax Pharmaceuticals board of directors from January 2014 to February 2017. From July 2007 through December 2016, Mr. Shea served as Senior Vice President and Chief Financial Officer of Momenta Pharmaceuticals Inc., a publicly traded biotechnology company, and was its Vice President and Chief Financial Officer since October 2003. Prior to joining Momenta, Mr. Shea served as Chief Operating Officer and Chief Financial Officer of Variagenics Inc., a publicly traded pharmacogenomics company, and as Vice President, Finance of Genetics Institute, Inc., a publicly traded biotechnology company. Mr. Shea received an A.B. from Princeton University and an M.B.A. from the Public Management Program at Boston University.
- Peter Barrett
-
Peter Barrett，2002年加入早期生命科学风险投资基金Atlas Venture，是生命科学集团的合伙人，曾参与创建多家治疗和药物发现平台公司。此前，他是Celera Genomics的联合创始人、执行副总裁兼首席商务官，该公司于2001年宣布首次成功进行人类基因组测序。在此之前，Barrett博士曾在Perkin-Elmer公司担任多个高级管理职位，最近担任企业规划和业务发展副总裁，在那里他经营着多项业务，并通过一系列许可协议、合作伙伴关系和收购帮助大幅扩展其生命科学产品组合。他目前担任上市公司Synlogic, Inc.的董事长，并且是私人控股的Obsidian Therapeutics，Inc.的董事会成员。Barrett博士还是哈佛商学院的执行研究员，并且是Blavatnik Fellowship项目关键顾问委员会的主席。Barrett博士在洛厄尔技术学院（现称马萨诸塞大学洛厄尔分校）获得化学理学学士学位，并在东北大学获得分析化学博士学位。
Peter Barrett,joined Atlas Venture, an early-stage life sciences venture capital fund, in 2002 and is a partner in the life sciences group, where he has been involved in the creation of several therapeutic and drug discovery platform companies. Previously, he was a co-founder, Executive Vice President and Chief Business Officer of Celera Genomics which in 2001 announced the first successful sequencing of the human genome. Prior to that, Dr. Barrett held several senior management positions at The Perkin-Elmer Corporation, most recently serving as Vice President, Corporate Planning and Business Development, where he operated several businesses and helped to greatly expand its life sciences portfolio through a series of licensing agreements, partnerships and acquisitions. He currently serves as the Chairman of Synlogic, Inc., which is publicly traded, and is a board member of privately held Obsidian Therapeutics, Inc. Dr. Barrett is also an executive fellow at the Harvard Business School and is the chair of the key advisory board of the Blavatnik Fellowship program. Dr. Barrett previously served on the board of Larimar Therapeutics, Inc., a publicly traded company, until 2023. In addition, Dr. Barrett is a board member of Nucleate, a student run non-profit organization representing the global community of bio-innovators. Dr. Barrett received his Bachelor of Science degree in chemistry from Lowell Technological Institute (now known as the University of Massachusetts, Lowell) and his doctoral degree in analytical chemistry from Northeastern University. - Peter Barrett，2002年加入早期生命科学风险投资基金Atlas Venture，是生命科学集团的合伙人，曾参与创建多家治疗和药物发现平台公司。此前，他是Celera Genomics的联合创始人、执行副总裁兼首席商务官，该公司于2001年宣布首次成功进行人类基因组测序。在此之前，Barrett博士曾在Perkin-Elmer公司担任多个高级管理职位，最近担任企业规划和业务发展副总裁，在那里他经营着多项业务，并通过一系列许可协议、合作伙伴关系和收购帮助大幅扩展其生命科学产品组合。他目前担任上市公司Synlogic, Inc.的董事长，并且是私人控股的Obsidian Therapeutics，Inc.的董事会成员。Barrett博士还是哈佛商学院的执行研究员，并且是Blavatnik Fellowship项目关键顾问委员会的主席。Barrett博士在洛厄尔技术学院（现称马萨诸塞大学洛厄尔分校）获得化学理学学士学位，并在东北大学获得分析化学博士学位。
- Peter Barrett,joined Atlas Venture, an early-stage life sciences venture capital fund, in 2002 and is a partner in the life sciences group, where he has been involved in the creation of several therapeutic and drug discovery platform companies. Previously, he was a co-founder, Executive Vice President and Chief Business Officer of Celera Genomics which in 2001 announced the first successful sequencing of the human genome. Prior to that, Dr. Barrett held several senior management positions at The Perkin-Elmer Corporation, most recently serving as Vice President, Corporate Planning and Business Development, where he operated several businesses and helped to greatly expand its life sciences portfolio through a series of licensing agreements, partnerships and acquisitions. He currently serves as the Chairman of Synlogic, Inc., which is publicly traded, and is a board member of privately held Obsidian Therapeutics, Inc. Dr. Barrett is also an executive fellow at the Harvard Business School and is the chair of the key advisory board of the Blavatnik Fellowship program. Dr. Barrett previously served on the board of Larimar Therapeutics, Inc., a publicly traded company, until 2023. In addition, Dr. Barrett is a board member of Nucleate, a student run non-profit organization representing the global community of bio-innovators. Dr. Barrett received his Bachelor of Science degree in chemistry from Lowell Technological Institute (now known as the University of Massachusetts, Lowell) and his doctoral degree in analytical chemistry from Northeastern University.
高管简历
中英对照 | 中文 | 英文- Mary Beth Dooley
Mary Beth Dooley自2025年1月1日起担任Synlogic, Inc.首席执行官、自2024年3月18日起担任Synlogic, Inc.首席财务官，She previoly自2023年11月起担任Synlogic, Inc.财务负责人，在此之前自2018年6月起担任Synlogic, Inc.控制人。她负责领导公司的财务战略、规划、企业会计和运营。在加入Synlogic之前，Dooley女士于2014年7月至2018年5月在井寺制药担任财务规划分析高级经理，在此之前，于2012年9月至2014年7月担任普华永道会计师事务所的合伙人。在加入普华永道会计师事务所之前，她曾在波士顿私人银行和TRT公司担任投资管理和TRT部门的助理副总裁。杜利女士在贝茨学院获得经济学学士学位，并在东北大学获得会计学MBA和硕士学位。
Mary Beth Dooley has served as Synlogic, Inc. Principal Executive Officer since January 1, 2025, Synlogic, Inc. Principal Financial Officer since March 18, 2024, and she previoly served as Synlogic, Inc. Head of Finance since November 2023 and prior to that as Synlogic, Inc. Controller since June 2018. She is responsible for leading the Company's financial strategy, planning, corporate accounting and operations. Prior to joining Synlogic, Ms. Dooley worked as a senior manager of financial planning analysis at Idera Pharmaceuticals from July 2014 to May 2018, and prior to that, as an associate with PricewaterhoeCoopers from September 2012 to July 2014. Prior to joining PricewaterhoeCoopers, she served as an Assistant Vice President at Boston Private Bank & Trt Company, in the Investment Management & Trt Department. Ms. Dooley received a B.S. in Economics from Bates College and an M.B.A. and a M.S. in Accounting from Northeastern University.- Mary Beth Dooley自2025年1月1日起担任Synlogic, Inc.首席执行官、自2024年3月18日起担任Synlogic, Inc.首席财务官，She previoly自2023年11月起担任Synlogic, Inc.财务负责人，在此之前自2018年6月起担任Synlogic, Inc.控制人。她负责领导公司的财务战略、规划、企业会计和运营。在加入Synlogic之前，Dooley女士于2014年7月至2018年5月在井寺制药担任财务规划分析高级经理，在此之前，于2012年9月至2014年7月担任普华永道会计师事务所的合伙人。在加入普华永道会计师事务所之前，她曾在波士顿私人银行和TRT公司担任投资管理和TRT部门的助理副总裁。杜利女士在贝茨学院获得经济学学士学位，并在东北大学获得会计学MBA和硕士学位。
- Mary Beth Dooley has served as Synlogic, Inc. Principal Executive Officer since January 1, 2025, Synlogic, Inc. Principal Financial Officer since March 18, 2024, and she previoly served as Synlogic, Inc. Head of Finance since November 2023 and prior to that as Synlogic, Inc. Controller since June 2018. She is responsible for leading the Company's financial strategy, planning, corporate accounting and operations. Prior to joining Synlogic, Ms. Dooley worked as a senior manager of financial planning analysis at Idera Pharmaceuticals from July 2014 to May 2018, and prior to that, as an associate with PricewaterhoeCoopers from September 2012 to July 2014. Prior to joining PricewaterhoeCoopers, she served as an Assistant Vice President at Boston Private Bank & Trt Company, in the Investment Management & Trt Department. Ms. Dooley received a B.S. in Economics from Bates College and an M.B.A. and a M.S. in Accounting from Northeastern University.